Your session is about to expire
← Back to Search
CAR T-cell Therapy for Acute Myeloid Leukemia
Study Summary
This trial is testing whether combining two ways of fighting cancer, T cells and antibodies, will work better than using them separately to fight cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have an active HIV or HTLV infection.My tumor is CLL-1 positive with at least 30% CLL-1 blasts.I have AML (not APL) that hasn't responded to treatment and am eligible for a stem cell transplant.I am 75 years old or younger.I need a procedure to collect blood cells for my treatment.I am currently on high-dose steroids or other immune-suppressing drugs for GVHD.My hemoglobin level is at least 7.0 g/dL, transfusions are okay.I have an ongoing infection that isn't getting better despite treatment.I have been diagnosed with acute promyelocytic leukemia.You are expected to live for at least 12 weeks.I do not have an active second cancer or was treated for another cancer within the last 2 years.
- Group 1: CLL-1.CAR
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the enrollment phase of this trial still open?
"Per the data hosted on clinicaltrials.gov, this investigational trial is still open for recruitment; it was first posted on July 9th 2020 and most recently updated November 21st 2022."
Has the FDA sanctioned CLL-1.CAR T cells for medicinal use?
"Our assessment of CLL-1.CAR T cell safety is a 1 on the 1 to 3 scale due to limited data regarding their efficacy and level of security in this Phase 1 trial."
How many individuals are partaking in the research project?
"Affirmative. Clinicaltrials.gov evidences that this research endeavor, which was uploaded on July 9th 2020, is actively enrolling participants. Only 18 individuals are required--all of whom have to be recruited from a single medical centre."
Share this study with friends
Copy Link
Messenger